HDT Bio
Seattle
About HDT Bio
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission is to maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $70.0M
- Funding stage: Seed
- Last round: Grant (Oct 2023)
- Website: hdt.bio
- Phone: (206) 704-6446
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/hdt-bio-89696 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.